In Brief: FDA's Medical Imaging Drugs Advisory Committee
This article was originally published in The Gray Sheet
FDA's Medical Imaging Drugs Advisory Committee: Meeting July 22 at the Holiday Inn-Bethesda in Bethesda, Maryland. The committee will review Cytogen's Prostascint product license application, according to the June 24 Federal Register. Prostascint is a "radiolabeled monoclonal antibody designed to detect sites of metastatic cancer which express the prostate specific membrane antigen." For more information, contact FDA's William Freas or Sheila Langford, 301/827-0314...
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.